Diffuse Large B Cell Lymphoma Activated B Cell Type C1333296
An aggressive form of non-Hodgkin lymphoma arising from B cells. Typically treated with chemotherapy regimens like R-CHOP, though outcomes vary.
Key facts at a glance
- ICD-10
- C83.30, C83.36, C83.32
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Lymphadenopathy
(hematologic)B symptoms (fever, night sweats, weight loss)
(hematologic)Fatigue
(hematologic)Splenomegaly
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
R-CHOP chemotherapy regimen
Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone represents the standard first-line treatment for diffuse large B-cell lymphoma. Monoclonal antibody therapy targets CD20 on malignant B-cells.
Additional treatment options
Polatuzumab vedotin-based regimens
For relapsed or refractory disease, polatuzumab vedotin (antibody-drug conjugate) combined with bendamustine and rituximab offers an alternative when standard therapy fails.
medicationStem cell transplantation
High-dose chemotherapy followed by autologous stem cell rescue is considered for patients with high-risk disease or those who achieve remission but have high relapse risk.
procedureCorticosteroid therapy
Short-term high-dose corticosteroids such as dexamethasone are used for rapid disease control and symptom relief, particularly in patients with bulky disease or urgent symptoms.
medicationResponse assessment and surveillance
Regular imaging (CT/PET scans) and laboratory studies to assess treatment response, detect residual disease, and monitor for relapse. Includes periodic bone marrow evaluation when indicated.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Diffuse Large B Cell Lymphoma Activated B Cell Type C1333296?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Diffuse Large B Cell Lymphoma Activated B Cell Type C1333296. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy